JP2005526790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526790A5 JP2005526790A5 JP2003577900A JP2003577900A JP2005526790A5 JP 2005526790 A5 JP2005526790 A5 JP 2005526790A5 JP 2003577900 A JP2003577900 A JP 2003577900A JP 2003577900 A JP2003577900 A JP 2003577900A JP 2005526790 A5 JP2005526790 A5 JP 2005526790A5
- Authority
- JP
- Japan
- Prior art keywords
- dysfunction
- erectile
- female sexual
- female
- sexual dysfunction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000004064 dysfunction Effects 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36545402P | 2002-03-19 | 2002-03-19 | |
| PCT/US2003/008448 WO2003080074A1 (en) | 2002-03-19 | 2003-03-19 | Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526790A JP2005526790A (ja) | 2005-09-08 |
| JP2005526790A5 true JP2005526790A5 (enExample) | 2006-03-09 |
Family
ID=28454658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577900A Withdrawn JP2005526790A (ja) | 2002-03-19 | 2003-03-19 | アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060004190A1 (enExample) |
| EP (1) | EP1496915A1 (enExample) |
| JP (1) | JP2005526790A (enExample) |
| KR (1) | KR20050008658A (enExample) |
| CN (1) | CN1720054A (enExample) |
| AU (1) | AU2003223304A1 (enExample) |
| BR (1) | BR0308567A (enExample) |
| CA (1) | CA2479372A1 (enExample) |
| WO (1) | WO2003080074A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| FR2939436B1 (fr) * | 2008-12-10 | 2010-12-17 | Sanofi Aventis | Synthese de morphine-6-glucuronide ou de l'un de ses derives |
| HUE028121T2 (en) | 2009-06-12 | 2016-11-28 | Cynapsus Therapeutics Inc | Sublingual apomorphine |
| KR102161392B1 (ko) | 2010-12-16 | 2020-10-05 | 선오비온 파마슈티컬스 인코포레이티드 | 설하 필름 |
| MX2014014902A (es) | 2012-06-05 | 2015-03-04 | Neuroderm Ltd | Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas. |
| KR20160108828A (ko) | 2013-11-11 | 2016-09-20 | 임팩스 라보라토리즈, 인코포레이티드 | 신속하게 붕괴되는 제형 및 사용 방법 |
| US20170368052A1 (en) * | 2014-12-23 | 2017-12-28 | Neuroderm, Ltd. | Crystal forms of apomorphine and uses thereof |
| US10729710B2 (en) | 2017-11-24 | 2020-08-04 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| WO2020234277A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
| EP3972970A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| EP3972971A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
| EP3972959A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| CN114773409B (zh) * | 2022-04-27 | 2023-12-15 | 江西艾立斯特生物科技有限公司 | 一种2,3,4,6-四-o-乙酰基-吡喃葡萄糖的制备方法 |
| US20250361252A1 (en) | 2022-06-15 | 2025-11-27 | Ever Neuro Pharma Gmbh | Apomorphine prodrugs and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4785014A (en) * | 1985-06-07 | 1988-11-15 | Yale University | Use of clonidine in memory enhancement |
| DK0689438T3 (da) * | 1993-03-26 | 2003-09-29 | Franciscus Wilhelmus He Merkus | Farmaceutiske præparater til intranasal administration af apomorfin |
| ES2143049T3 (es) * | 1994-04-22 | 2000-05-01 | Pentech Pharmaceuticals Inc | Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil. |
| US6121276A (en) * | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
| US5888534A (en) * | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| US6266560B1 (en) * | 1998-06-19 | 2001-07-24 | Genetronics, Inc. | Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction |
| US6001845A (en) * | 1998-06-19 | 1999-12-14 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
| US6011043A (en) * | 1998-06-19 | 2000-01-04 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
| US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
| US6291471B1 (en) * | 1998-12-17 | 2001-09-18 | Abb Holdings, Inc. | Use of apomorphine for the treatment of organic erectile dysfunction in males |
| US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
| HUP0301773A3 (en) * | 2000-04-07 | 2006-02-28 | Tap Pharmaceutical Prod Inc | Apomorphine derivatives and methods for their use |
-
2003
- 2003-03-19 CA CA002479372A patent/CA2479372A1/en not_active Abandoned
- 2003-03-19 US US10/508,160 patent/US20060004190A1/en not_active Abandoned
- 2003-03-19 BR BRPI0308567-8A patent/BR0308567A/pt not_active IP Right Cessation
- 2003-03-19 WO PCT/US2003/008448 patent/WO2003080074A1/en not_active Ceased
- 2003-03-19 CN CNA038114879A patent/CN1720054A/zh active Pending
- 2003-03-19 AU AU2003223304A patent/AU2003223304A1/en not_active Abandoned
- 2003-03-19 JP JP2003577900A patent/JP2005526790A/ja not_active Withdrawn
- 2003-03-19 KR KR10-2004-7014649A patent/KR20050008658A/ko not_active Withdrawn
- 2003-03-19 EP EP03719419A patent/EP1496915A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005526790A5 (enExample) | ||
| JP2004525194A5 (enExample) | ||
| JP2005519316A5 (enExample) | ||
| JP2005526058A5 (enExample) | ||
| MA26600A1 (fr) | Traitement du dysfonctionnement sexuel feminin. | |
| JP2005508306A5 (enExample) | ||
| JP2004210767A5 (enExample) | ||
| JP2006503588A5 (enExample) | ||
| CY2012028I1 (el) | Η χρηση δαποξετινης, ενος ταχειας-εναρξης επιλεκτικου αναστολεα εκ νεου αναληψης σepοτονινης για την θepαπευτικη αντιμετωπιση σεξουαλικης δυσλειτουργιας | |
| JP2002179603A5 (enExample) | ||
| WO2005099702A3 (en) | R(-)-11-hydroxyaporphine derivatives and uses thereof | |
| GB0225908D0 (en) | Treatment of female sexual dysfunction | |
| NO20024442L (no) | Behandling av seksuell dysfunksjon med apomorfin | |
| JP2005527457A5 (enExample) | ||
| NO20032189L (no) | Behandling av antidepresjonsmiddel-indusert seksuell dysfunksjon med apomorfin | |
| DE60331769D1 (de) | Sten in der behandlung von u.a. sexueller dysfunktion | |
| EP1648430A4 (en) | TREATMENT FOR EJACULATIO PRAECOX | |
| AP2380A (en) | Use of surfactants in the production of metal. | |
| JP2005536763A5 (enExample) | ||
| GB2386555B (en) | Treatment of female sexual dysfunction | |
| JP2005536335A5 (enExample) | ||
| JP2005506372A5 (enExample) | ||
| GB0318706D0 (en) | Selective serotonin reuptake inhibitors in the treatment of disease | |
| GB0316673D0 (en) | Treatment of female sexual dysfunction | |
| GB0202282D0 (en) | Treatment of male sexual dysfunction |